An Open-Label CBD Dose-Escalation Study Could Not Establish Placebo-Adjusted Motor Benefit
A small open-label CBD dose-escalation study in Parkinson’s disease reported improved motor scores and frequent mild adverse effects. Those observations inform feasibility and tolerability, but do not establish how much improvement CBD produced beyond placebo or other influences.
Escalation and completion were part of the design
The review describes Leehey and colleagues’ study of purified CBD in patients with Parkinson’s disease and resting tremor. Thirteen entered and ten completed the study. Doses were increased, with the highest tolerated level maintained for a limited interval.
The review reports motor-score and nighttime-sleep improvements, alongside adverse effects such as diarrhea, somnolence and fatigue. Absence of serious events in a small sample is not a guarantee of safety across larger populations or longer exposure.
Observed change is not a controlled treatment effect
Participants and investigators knew treatment was being given. Without a placebo group, changes cannot be cleanly separated from expectations, natural variation, concurrent care or repeated measurement.
A dose-escalation procedure also does not randomly compare every dose level. It cannot establish that the highest tolerated dose is the most effective dose or identify a universal optimum.
Tolerability and efficacy need separate conclusions
A participant’s ability to continue treatment and a change in a symptom scale answer different questions. Completion, adverse events and the observation period should accompany any benefit claim.
The review presents a preliminary clinical study, not definitive proof of motor efficacy. Its findings can help design controlled research while preserving the uncertainty about the intervention’s specific contribution to the reported improvement.
Related: Why outcomes must remain specific to the tested domain.
Research cited
Șolea R; Șerban E; Călugăr-Solea SF; et al.. Pharmaceuticals (2026). Cannabis and Cannabinoids: The Medical Potential of Cannabidiol in Mental and Neurological Disorders.
